156 related articles for article (PubMed ID: 37902714)
1. Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec versus extended half-life factor IX therapies for severe or moderately severe haemophilia B.
Klamroth R; Bonner A; Gomez K; Monahan PE; Szafranski K; Zhang X; Walsh S; Wang D; Yan S
Haemophilia; 2024 Jan; 30(1):75-86. PubMed ID: 37902714
[TBL] [Abstract][Full Text] [Related]
2. Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial.
Coppens M; Pipe SW; Miesbach W; Astermark J; Recht M; van der Valk P; Ewenstein B; Pinachyan K; Galante N; Le Quellec S; Monahan PE; Leebeek FWG;
Lancet Haematol; 2024 Apr; 11(4):e265-e275. PubMed ID: 38437857
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B.
Shah J; Kim H; Sivamurthy K; Monahan PE; Fries M
Curr Med Res Opin; 2023 Feb; 39(2):227-237. PubMed ID: 36285399
[TBL] [Abstract][Full Text] [Related]
4. Matching-Adjusted Indirect Comparison of Recombinant Factor IX Albumin Fusion Protein Versus Recombinant Factor IX Fc Fusion Protein for Weekly Prophylactic Treatment of Hemophilia B.
Guillet B; Yan S; Hooper B; Drelich D; Steenkamp J; Tomic R; Mancuso ME
Adv Ther; 2024 Feb; 41(2):649-658. PubMed ID: 38070040
[TBL] [Abstract][Full Text] [Related]
5. Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency).
Sekayan T; Simmons DH; von Drygalski A
Expert Opin Biol Ther; 2023; 23(12):1173-1184. PubMed ID: 37962325
[TBL] [Abstract][Full Text] [Related]
6. Etranacogene Dezaparvovec: First Approval.
Heo YA
Drugs; 2023 Mar; 83(4):347-352. PubMed ID: 36802324
[TBL] [Abstract][Full Text] [Related]
7. Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B.
Castaman G; Coppens M; Pipe SW
Expert Rev Hematol; 2023; 16(12):919-932. PubMed ID: 37882214
[TBL] [Abstract][Full Text] [Related]
8. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.
Pipe SW; Leebeek FWG; Recht M; Key NS; Castaman G; Miesbach W; Lattimore S; Peerlinck K; Van der Valk P; Coppens M; Kampmann P; Meijer K; O'Connell N; Pasi KJ; Hart DP; Kazmi R; Astermark J; Hermans CRJR; Klamroth R; Lemons R; Visweshwar N; von Drygalski A; Young G; Crary SE; Escobar M; Gomez E; Kruse-Jarres R; Quon DV; Symington E; Wang M; Wheeler AP; Gut R; Liu YP; Dolmetsch RE; Cooper DL; Li Y; Goldstein B; Monahan PE
N Engl J Med; 2023 Feb; 388(8):706-718. PubMed ID: 36812434
[TBL] [Abstract][Full Text] [Related]
9. Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis.
Hermans C; Marino R; Lambert C; Mangles S; Sommerer P; Rives V; Maro G; Malcangi G
Adv Ther; 2020 Jun; 37(6):2988-2998. PubMed ID: 32333327
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of rFIXFc versus rIX-FP for the Treatment of Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PROLONG-9FP Trials.
Astermark J; Wojciechowski P; Aballéa S; Hakimi Z; Nazir J; Klamroth R
J Blood Med; 2021; 12():613-621. PubMed ID: 34285621
[TBL] [Abstract][Full Text] [Related]
11. Etranacogene dezaparvovec for hemophilia B gene therapy.
Thornburg CD
Ther Adv Rare Dis; 2021; 2():26330040211058896. PubMed ID: 37181105
[TBL] [Abstract][Full Text] [Related]
12. Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B.
Von Drygalski A; Giermasz A; Castaman G; Key NS; Lattimore S; Leebeek FWG; Miesbach W; Recht M; Long A; Gut R; Sawyer EK; Pipe SW
Blood Adv; 2019 Nov; 3(21):3241-3247. PubMed ID: 31698454
[TBL] [Abstract][Full Text] [Related]
13. Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy.
von Drygalski A; Gomez E; Giermasz A; Castaman G; Key NS; Lattimore SU; Leebeek FWG; Miesbach WA; Recht M; Gut R; Dolmetsch R; Monahan PE; Le Quellec S; Pipe SW
Blood Adv; 2023 Oct; 7(19):5671-5679. PubMed ID: 36490302
[TBL] [Abstract][Full Text] [Related]
14. Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX-FP.
Davis J; Yan S; Matsushita T; Alberio L; Bassett P; Santagostino E
J Med Econ; 2019 Oct; 22(10):1014-1021. PubMed ID: 31094591
[No Abstract] [Full Text] [Related]
15. Assessing health plan payer's budget impact of etranacogene dezaparvovec for the treatment of hemophilia B in the United States.
Wilson M; McDade C; Thiruvillakkat K; Rouse R; Sivamurthy K; Yan S
J Manag Care Spec Pharm; 2024 Apr; ():1-12. PubMed ID: 38625717
[TBL] [Abstract][Full Text] [Related]
16. Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study.
Fischer K; Kulkarni R; Nolan B; Mahlangu J; Rangarajan S; Gambino G; Diao L; Ramirez-Santiago A; Pierce GF; Allen G
Lancet Haematol; 2017 Feb; 4(2):e75-e82. PubMed ID: 28159192
[TBL] [Abstract][Full Text] [Related]
17. Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial.
Kenet G; Chambost H; Male C; Lambert T; Halimeh S; Chernova T; Mancuso ME; Curtin J; Voigt C; Li Y; Jacobs I; Santagostino E;
Thromb Haemost; 2016 Sep; 116(4):659-68. PubMed ID: 27583313
[TBL] [Abstract][Full Text] [Related]
18. Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients.
Martinowitz U; Lissitchkov T; Lubetsky A; Jotov G; Barazani-Brutman T; Voigt C; Jacobs I; Wuerfel T; Santagostino E
Haemophilia; 2015 Nov; 21(6):784-90. PubMed ID: 25990590
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors.
Pochopien M; Tytuła A; Toumi M; Falk A; Martone N; Hakimi Z; Eriksson D
Adv Ther; 2024 Jun; 41(6):2307-2323. PubMed ID: 38652439
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery.
Négrier C; Abdul Karim F; Lepatan LM; Lienhart A; López-Fernández MF; Mahlangu J; Pabinger I; Li Y; Wolko D; Voigt C; Jacobs I; Santagostino E
Haemophilia; 2016 Jul; 22(4):e259-66. PubMed ID: 27333467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
